

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
25 November 2021 (25.11.2021)



(10) International Publication Number
WO 2021/234380 A1

(51) International Patent Classification:
C12Q 1/689 (2018.01)

(21) International Application Number:
PCT/GB2021/051206

(22) International Filing Date:
19 May 2021 (19.05.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2007452.2 19 May 2020 (19.05.2020) GB

(71) Applicant: **MICROBIOTICA LIMITED** [GB/GB];
Chesterford Research Park, Little Chesterford, Cambridge
CB10 1XL (GB).

(72) Inventors: **ROBINSON, Matthew**; Microbiotica Limited,
Chesterford Research Park, Little Chesterford, Cambridge
CB10 1XL (GB). **LAWLEY, Trevor**; Microbiotica Lim-
ited, Chesterford Research Park, Little Chesterford, Cam-
bridge CB10 1XL (GB). **ROMANOS, Michael**; Microbi-
otica Limited, Chesterford Research Park, Little Chester-
ford, Cambridge CB10 1XL (GB). **VERVIER, Kevin**;
Microbiotica Limited, Chesterford Research Park, Little
Chesterford, Cambridge CB10 1XL (GB). **HARRIS, Si-
mon**; Microbiotica Limited, Chesterford Research Park,
Little Chesterford, Cambridge CB10 1XL (GB). **BAK-
DASH, Ghaith**; Microbiotica Limited, Chesterford Re-
search Park, Little Chesterford, Cambridge CB10 1XL
(GB). **POPPLE, Amy**; Microbiotica Limited, Chester-
ford Research Park, Little Chesterford, Cambridge CB10
1XL (GB). **KLISKO, Dominika**; Microbiotica Limited,
Chesterford Research Park, Little Chesterford, Cambridge
CB10 1XL (GB).

(74) Agent: **APPLEYARD LEES IP LLP**, 15 Clare Road, Hal-
ifax Yorkshire HX1 2HY (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: THERAPEUTIC BACTERIAL COMPOSITION

(57) Abstract: The invention relates to bacterial compositions useful in the treatment of cancer. In particular, the compositions can be used as a co-therapy with an immune checkpoint therapy. The invention also relates to methods for identifying a subject that will respond to therapy with an immune checkpoint inhibitor comprising determining the abundance of bacteria in a biological sample from said subject.

WO 2021/234380 A1